Ironwood Pharmaceuticals (IRWD) Projected to Post Earnings on Thursday

Key Points

• Ironwood Pharmaceuticals is expected to release its Q2 2025 earnings report on August 14th, with analysts predicting earnings of ($0.02) per share and $62.02 million in revenue.
• In the last quarter, Ironwood reported a loss of ($0.14) EPS, falling short of the expected ($0.05), with actual revenue of $41.14 million, significantly below analyst estimates of $67.02 million.
• Hedge funds have substantially increased their holdings in Ironwood, with Millennium Management increasing its stake by 186.6% during the first quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Ironwood Pharmaceuticals to post earnings of ($0.02) per share and revenue of $62.02 million for the quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its earnings results on Thursday, August 14th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 1.87% and a negative net margin of 9.89%. On average, analysts expect Ironwood Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Up 9.3%

IRWD traded up $0.08 on Thursday, hitting $0.88. 5,245,860 shares of the stock traded hands, compared to its average volume of 1,178,772. The business has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $1.20. The firm has a market capitalization of $142.40 million, a PE ratio of -4.40 and a beta of 0.33. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $6.14.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IRWD. Wells Fargo & Company restated an "equal weight" rating and issued a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners lowered their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Jefferies Financial Group reissued a "hold" rating and set a $0.70 price target (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Finally, Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $4.78.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its position in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock valued at $9,349,000 after acquiring an additional 4,140,439 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock worth $5,160,000 after purchasing an additional 3,092,475 shares during the period. AQR Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 535.8% during the first quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company's stock worth $3,710,000 after purchasing an additional 2,126,889 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 72.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company's stock worth $2,316,000 after buying an additional 660,144 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Ironwood Pharmaceuticals during the 1st quarter worth approximately $113,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.